

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 23, 2018
PDL Changes Effective Date: January 1, 2019



The following changes will be made to the Preferred Drug List (PDL), effective January 1, 2019, pending recommendation and/or approval by the P&T Committee, DOM, and DOM's Executive Director.

For a comprehensive PDL, refer to <http://www.medicaid.ms.gov/providers/pharmacy/preferred-drug-list/>.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
Alzheimer's Agents, Cholinesterase Inhibitors	Rivastigmine Patch
Analgesics/Anesthetics (Topical)	Pennsaid Solution
Angiotensin Modulators, ARB Combinations	Olmesartan/Amlodipine
Anticonvulsants, Adjuvants	Oxcarbazepine Suspension
Antiretrovirals, CD4 Directed HIV-1 Inhibitor	Trogarzo
Antiretrovirals, Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	Ziagen Solution
Antiretrovirals, Protease Inhibitors (Non-Peptidic)	Prezcobix
Antiretrovirals, Protease Inhibitors (Peptidic)	Atazanavir
Atopic Dermatitis	Eucrisa
Bronchodilators and COPD Agents, Anticholinergic-Beta Agonist Combinations	Bevespi
Colony Stimulating Factors	Neupogen Vial
Cystic Fibrosis Agents	Tobramycin labeler 00093, 00781, 65162, 17478
Erythropoiesis Stimulating Proteins	Mircera
Glucocorticoids (Inhaled), Glucocorticoids	QVAR Redihaler
Hereditary Angioedema, Icatibant Acetate	Firazyr
Hypoglycemics, Incretin Mimetics/Enhancers	Byetta
Hypoglycemics, Sodium Glucose Transporter 2 Inhibitors	Invokana
Hypoglycemics, Sodium Glucose Transporter 2 Inhibitors	Invokamet

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 23, 2018
PDL Changes Effective Date: January 1, 2019



IBS/SBS Agents/Selected GI Agents, Irritable Bowel Syndrome Constipation	Movantik
Movement Disorder Agents	Ingrezza
Movement Disorder Agents	Tetrabenazine
Ophthalmic Anti-Inflammatories	Fluorometholone
Ophthalmic Anti-Inflammatories	FML Forte
Ophthalmic Anti-Inflammatories	Nevanac
Ophthalmic Anti-Inflammatories	Pred Mild
Ophthalmics Antibiotics	Moxifloxacin
Ophthalmics Antibiotics	Ofloxacin
Ophthalmics Antibiotics, Antibiotic-Steroid Combinations	Neomycin/Bacitracin/Polymyxin/Hydrocortisone Ointment
Ophthalmics for Allergic Conjunctivitis	Alrex
Ophthalmics for Allergic Conjunctivitis	Azelastine
Parathyroid Agents	Rocaltrol Solution
Parathyroid Agents	Zemplar
Phosphate Binders	Sevelamer Carbonate Tablet
Platelet Aggregation Inhibitors	Prasugrel
Stimulants & Related Agents, Short Acting	Dextroamphetamine Sulfate IR Tablet
Ulcerative Colitis and Crohn's Agents, Oral	Delzicol

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Alzheimer's Agents, Cholinesterase Inhibitors	Exelon Patch
Antibiotics (Vaginal)	Clindamycin Cream
Antibiotics (Vaginal)	Vandazole
Anticonvulsants, Adjuvants	Carbamazepine XR
Anticonvulsants, Adjuvants	Trileptal Suspension

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 23, 2018
PDL Changes Effective Date: January 1, 2019



NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Antiemetics, Antiemetic Combinations	Bonjesta
Antiemetics, Antiemetic Combinations	Diclegis
Antifungals (Vaginal)	Miconazole 3 Cream
Antifungals (Vaginal)	Terconazole
Antimigraine Agents, Triptans	Eletriptan
Antiretrovirals, Combination Products - NRTIs	Abacavir/Lamivudine/Zidovudine
Antiretrovirals, Combination Products - NRTIs	Trizivir
Antiretrovirals, Combination Products – Nucleoside & Nucleotide Analogs & NNRTIs	Atripla
Antiretrovirals, Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)	Nevirapine
Antiretrovirals, Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)	Nevirapine ER
Antiretrovirals, Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	Didanosine DR (250mg & 400mg)
Antiretrovirals, Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	Stavudine
Antiretrovirals, Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	Videx Solution
Antiretrovirals, Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	Viread
Antiretrovirals, Protease Inhibitors (Peptidic)	Reyataz
Antiretrovirals, Protease Inhibitors (Peptidic)	Viracept
Bronchodilators and COPD Agents, Anticholinergic-Beta Agonist Combinations	Combivent Respimat*
Colony Stimulating Factors	Leukine
Colony Stimulating Factors	Zarxio
Cystic Fibrosis Agents	Bethkis
Cystic Fibrosis Agents	Kitabis
Cystic Fibrosis Agents	Tobramycin labeler 70644

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 23, 2018
PDL Changes Effective Date: January 1, 2019



NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Erythropoiesis Stimulating Proteins	Aranesp
Hepatitis B Treatment	Viread
Hereditary Angioedema, C1 Esterase Inhibitor	Berinert
Ophthalmics Antibiotics	Ciloxan Ointment
Ophthalmics Antibiotics	Tobrex Ointment
Ophthalmics Antibiotics	Vigamox
Ophthalmics for Allergic Conjunctivitis	Olopatadine 0.2%
Ophthalmics, Glaucoma Agents, Beta Blockers	Betaxolol
Ophthalmics, Glaucoma Agents, Carbonic Anhydrase Inhibitors	Azopt
Ophthalmics, Glaucoma Agents, Carbonic Anhydrase Inhibitors	Trusopt
Ophthalmics, Glaucoma Agents, Prostaglandin Analogs	Travatan Z
Otic Antibiotics	Neomycin/Polymyxin B/Hydrocortisone
Otic Antibiotics	Otiprio
Phosphate Binders	Renagel
Platelet Aggregation Inhibitors	Effient
Platelet Aggregation Inhibitors	Yosprala
Pulmonary Antihypertensives	Tracleer Suspension
Stimulants & Related Agents, Short Acting	Focalin
Ulcerative Colitis and Crohn's Agents, Rectal	Mesalamine

****Current users will be grandfathered.***